Patuto Nicola, Beglinger Christoph
Klinik für Gastroenterologie und Hepatologie, Universitätsspital Basel.
Praxis (Bern 1994). 2013 Aug 21;102(17):1046-52. doi: 10.1024/1661-8157/a001380.
Inflammatory bowel diseases (IBD) show an increase of prevalence in Switzerland. Industrialization and urbanisation correlate with an increase of incidence. IBD are the result of a continuum of interactions between genetic factors, the intestinal microbial flora, the immune system as well as environmental factors. Treatment for active Crohn's disease includes primarily systemically acting steroids for induction of remission, whereas azathioprine, methotrexate and TNF antibodies are used for maintenance of remission. Treatment for ulcerative colitis includes mostly systemic acting steroids for induction of remission and topically and systemically acting 5-ASA products and TNF antibodies for maintenance of remission. For mild active disease 5-ASA drugs are effective.
炎症性肠病（IBD）在瑞士的患病率呈上升趋势。工业化和城市化与发病率的增加相关。IBD是遗传因素、肠道微生物群、免疫系统以及环境因素之间一系列相互作用的结果。活动性克罗恩病的治疗主要包括使用全身作用的类固醇诱导缓解，而硫唑嘌呤、甲氨蝶呤和肿瘤坏死因子（TNF）抗体则用于维持缓解。溃疡性结肠炎的治疗大多包括使用全身作用的类固醇诱导缓解，以及使用局部和全身作用的5-氨基水杨酸（5-ASA）产品和TNF抗体维持缓解。对于轻度活动性疾病，5-ASA药物有效。
